Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Cytek Biosciences, Inc. (CTKB)

Cytek Biosciences Q3 revenue rises 2% to $53.2 million; net loss widens to $6.1 million

Mixed Impact 3 of 5 earnings Written later

Cytek Biosciences reported third-quarter 2026 revenue of $53.2 million, up 2% from a year earlier, and a GAAP gross margin of 59%, up from 53%. The net loss widened to $6.1 million from $5.5 million, and the company kept the midpoint of its full-year 2026 revenue guidance while narrowing the range to $208 million to $211 million.

Key points

  • Q3 2026 total revenue was $53.2 million, a 2% increase; U.S. revenue grew 12%.
  • Q3 2026 net loss was $6.1 million, compared with $5.5 million in Q3 2025; adjusted EBITDA was $0.7 million versus $2.5 million.
  • Full-year 2026 revenue guidance midpoint maintained; range narrowed to $208 million to $211 million.
  • Cash, cash equivalents, restricted cash and marketable securities were $256.3 million at September 30, 2026, down $5.7 million from June 30, 2026.

The filing

CompanyCytek Biosciences, Inc. (CTKB)
Form8-K, current report
Filed with the SECNov 4, 2026, 4:15 PM ET
Accession number0001193125-26-447300

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 04, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.